Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma

Hao Xing; Haibo Qiu; Xuemei Ding; Jun Han; Zhenli Li; Han Wu; Cunling Yan; Huijun Li; Ruilin Han; Han Zhang; Chao Li; Mingda Wang; Mengchao Wu; Feng Shen; Yijie Zheng; Tian Yang

doi:10.2217/bmm-2018-0414

Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma

Hao Xing
, Haibo Qiu
, Xuemei Ding
, Jun Han
, Zhenli Li
, Han Wu
, Cunling Yan
, Huijun Li
, Ruilin Han
, Han Zhang
, Chao Li
, Mingda Wang
, Mengchao Wu
, Feng Shen
, Yijie Zheng
, Tian Yang

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Aim: To evaluate the diagnostic performance of serum AFU for early stage hepatocellular carcinoma (HCC). Methods: Concentration of AFU and AFP were measured in 512 patients. The performance was compared for AFU and AFP alone or in combination. Results: The area under the curve (AUC) for AFU was 0.68, with a sensitivity of 56.1% and specificity of 69.2% at the cut-off value of 24 U/l; whereas the AUC for AFP was 0.83, with a sensitivity of 58.2% and specificity of 85.2% at cut-off value of 20 ng/ml. The AUC of AFU alone or the combination with AFP were lower than that of AFP alone. Conclusion: AFU is a suboptimal biomarker for early detection of HCC.

Original language	English
Pages (from-to)	545-555
Number of pages	11
Journal	Biomarkers in Medicine
Volume	13
Issue number	7
DOIs	https://doi.org/10.2217/bmm-2018-0414
State	Published - 2019
Externally published	Yes

Keywords

area under the curve
biomarker
diagnostic performance
early detection
early stage-HCC
hepatocellular carcinoma
sensitivity
specificity
α-L-fucosidase
α-fetoprotein

Access to Document

10.2217/bmm-2018-0414

Cite this

@article{c4e3d8a4b54942ca8b2b0da112d48f2b,

title = "Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma",

abstract = "Aim: To evaluate the diagnostic performance of serum AFU for early stage hepatocellular carcinoma (HCC). Methods: Concentration of AFU and AFP were measured in 512 patients. The performance was compared for AFU and AFP alone or in combination. Results: The area under the curve (AUC) for AFU was 0.68, with a sensitivity of 56.1\% and specificity of 69.2\% at the cut-off value of 24 U/l; whereas the AUC for AFP was 0.83, with a sensitivity of 58.2\% and specificity of 85.2\% at cut-off value of 20 ng/ml. The AUC of AFU alone or the combination with AFP were lower than that of AFP alone. Conclusion: AFU is a suboptimal biomarker for early detection of HCC.",

keywords = "area under the curve, biomarker, diagnostic performance, early detection, early stage-HCC, hepatocellular carcinoma, sensitivity, specificity, α-L-fucosidase, α-fetoprotein",

author = "Hao Xing and Haibo Qiu and Xuemei Ding and Jun Han and Zhenli Li and Han Wu and Cunling Yan and Huijun Li and Ruilin Han and Han Zhang and Chao Li and Mingda Wang and Mengchao Wu and Feng Shen and Yijie Zheng and Tian Yang",

note = "Publisher Copyright: {\textcopyright} 2019 Future Medicine Ltd.",

year = "2019",

doi = "10.2217/bmm-2018-0414",

language = "English",

volume = "13",

pages = "545--555",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma

AU - Xing, Hao

AU - Qiu, Haibo

AU - Ding, Xuemei

AU - Han, Jun

AU - Li, Zhenli

AU - Wu, Han

AU - Yan, Cunling

AU - Li, Huijun

AU - Han, Ruilin

AU - Zhang, Han

AU - Li, Chao

AU - Wang, Mingda

AU - Wu, Mengchao

AU - Shen, Feng

AU - Zheng, Yijie

AU - Yang, Tian

PY - 2019

Y1 - 2019

N2 - Aim: To evaluate the diagnostic performance of serum AFU for early stage hepatocellular carcinoma (HCC). Methods: Concentration of AFU and AFP were measured in 512 patients. The performance was compared for AFU and AFP alone or in combination. Results: The area under the curve (AUC) for AFU was 0.68, with a sensitivity of 56.1% and specificity of 69.2% at the cut-off value of 24 U/l; whereas the AUC for AFP was 0.83, with a sensitivity of 58.2% and specificity of 85.2% at cut-off value of 20 ng/ml. The AUC of AFU alone or the combination with AFP were lower than that of AFP alone. Conclusion: AFU is a suboptimal biomarker for early detection of HCC.

AB - Aim: To evaluate the diagnostic performance of serum AFU for early stage hepatocellular carcinoma (HCC). Methods: Concentration of AFU and AFP were measured in 512 patients. The performance was compared for AFU and AFP alone or in combination. Results: The area under the curve (AUC) for AFU was 0.68, with a sensitivity of 56.1% and specificity of 69.2% at the cut-off value of 24 U/l; whereas the AUC for AFP was 0.83, with a sensitivity of 58.2% and specificity of 85.2% at cut-off value of 20 ng/ml. The AUC of AFU alone or the combination with AFP were lower than that of AFP alone. Conclusion: AFU is a suboptimal biomarker for early detection of HCC.

KW - area under the curve

KW - biomarker

KW - diagnostic performance

KW - early detection

KW - early stage-HCC

KW - hepatocellular carcinoma

KW - sensitivity

KW - specificity

KW - α-L-fucosidase

KW - α-fetoprotein

UR - https://www.scopus.com/pages/publications/85068726424

U2 - 10.2217/bmm-2018-0414

DO - 10.2217/bmm-2018-0414

M3 - Article

C2 - 31140827

AN - SCOPUS:85068726424

SN - 1752-0363

VL - 13

SP - 545

EP - 555

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

IS - 7

ER -

Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this